| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964212 | ASCEND THERAPS US | Effervescent compositions comprising phosphonates and methods related thereto |
Mar, 2023
(6 months ago) | |
| US7488496 | ASCEND THERAPS US | Effervescent compositions comprising bisphosphonates and methods related thereto |
Aug, 2023
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592195 | ASCEND THERAPS US | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Dec, 2031
(8 years from now) | |
Binosto is owned by Ascend Theraps Us.
Binosto contains Alendronate Sodium.
Binosto has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Binosto are:
- US7964212
- US7488496
Binosto was authorised for market use on 12 March, 2012.
Binosto is available in tablet, effervescent;oral dosage forms.
The generics of Binosto are possible to be released after 05 December, 2031.
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 12 March, 2012
Treatment: NA
Dosage: TABLET, EFFERVESCENT;ORAL
More Information on Dosage
BINOSTO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic